A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers
Authors:
- Anhye KimAKAnhye Kim
- Kyoung Soo LimKLKyoung Soo Lim
- Howard LeeHLHoward Lee
- Hyewon ChungHCHyewon Chung
- Seo Hyun YoonSYSeo Hyun Yoon
- Kyung-Sang YuKYKyung-Sang Yu
- Joo-Youn ChoJoo-Youn Cho
- In-Jin JangIJIn-Jin Jang
- Jae-Yong ChungJCJae-Yong Chung
- 1 July 2016
- journal article
- research article
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 31 (4) , 210-217
Abstract
Prolongation of the QT interval on an ECG is a surrogate marker for predicting the proarrhythmic potential of a drug under development. The aim of this study was to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine immediate release (IR) and escitalopram, in healthy individuals. This was a randomized, open-label, 4×4 Williams crossover study, with four single-dose treatments [placebo, 400 mg moxifloxacin (positive control), 20 mg escitalopram, and 100 mg quetiapine IR], conducted in 40 healthy volunteers. Serial blood samples for pharmacokinetics and ECG were collected. Individually, RR-corrected QTc intervals (QTcI) and placebo-adjusted changes from baseline values of QTcI (ΔΔQTcI) were evaluated. Lower-bound values of the one-sided 95% confidence interval for ΔΔQTcI of moxifloxacin with more than 5 ms confirmed the sensitivity of the assay. The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively. Peak effects of moxifloxacin and quetiapine IR on ΔΔQTcI were observed at approximately time to maximum concentration (Tmax), whereas that of escitalopram was observed 3 h after Tmax. The concentration-ΔΔQTcI relationships of quetiapine IR and escitalopram were relatively flat, as compared with that of moxifloxacin. The results demonstrated the validity of trial methodology and that quetiapine IR and escitalopram caused QT prolongation in healthy individuals. In addition, hysteresis of escitalopram-induced QTc prolongation. These results indicate that higher doses of these drugs could lead to greater QT prolongation in a dose-response manner.Keywords
This publication has 24 references indexed in Scilit:
- Quetiapine and the Need for a Thorough QT/QTc StudyJournal of Clinical Psychopharmacology, 2014
- Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reportsTherapeutic Advances in Psychopharmacology, 2013
- A Comparison of the Risk of QT Prolongation Among SSRIsAnnals of Pharmacotherapy, 2013
- Escitalopram block of hERG potassium channelsNaunyn-Schmiedeberg's Archives of Pharmacology, 2013
- Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implicationsCurrent Medical Research and Opinion, 2013
- Population Pharmacokinetic and Concentration-QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT StudiesThe Journal of Clinical Pharmacology, 2011
- The Noradrenergic Action in Antidepressant Treatments: Pharmacological and Clinical AspectsCNS Neuroscience & Therapeutics, 2010
- QuetiapineCNS Drugs, 2004
- Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden DeathDrugs, 2002
- Clinical aspects of ventricular arrhythmias associated with QT prolongationEuropean Heart Journal Supplements, 2001